Nurix Therapeutics, Inc. Forecasted to Post FY2025 Earnings of ($3.06) Per Share (NASDAQ:NRIX)

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Stock analysts at HC Wainwright issued their FY2025 earnings estimates for Nurix Therapeutics in a note issued to investors on Tuesday, June 18th. HC Wainwright analyst R. Burns expects that the company will post earnings of ($3.06) per share for the year. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($3.00) per share.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Wednesday, April 10th. The company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.04. The company had revenue of $16.59 million for the quarter, compared to analysts’ expectations of $14.58 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%.

A number of other equities research analysts have also recently issued reports on NRIX. Piper Sandler reaffirmed an “overweight” rating and issued a $35.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. Robert W. Baird upped their price objective on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Monday. Stephens began coverage on shares of Nurix Therapeutics in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 price objective for the company. Finally, JPMorgan Chase & Co. upped their price objective on shares of Nurix Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.80.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $18.44 on Wednesday. The company’s fifty day moving average price is $14.99 and its 200-day moving average price is $12.24. The firm has a market capitalization of $906.33 million, a price-to-earnings ratio of -6.93 and a beta of 2.17. Nurix Therapeutics has a one year low of $4.22 and a one year high of $18.90.

Hedge Funds Weigh In On Nurix Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of NRIX. ProShare Advisors LLC grew its stake in shares of Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after purchasing an additional 998 shares during the period. Public Employees Retirement System of Ohio raised its holdings in Nurix Therapeutics by 3.7% in the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after buying an additional 1,820 shares during the period. Raymond James & Associates raised its holdings in Nurix Therapeutics by 3.1% in the 4th quarter. Raymond James & Associates now owns 101,006 shares of the company’s stock valued at $1,042,000 after buying an additional 3,018 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Nurix Therapeutics by 67.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock valued at $138,000 after acquiring an additional 3,793 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Nurix Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 15,823 shares of the company’s stock valued at $163,000 after acquiring an additional 4,012 shares in the last quarter.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,499 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17. Following the transaction, the chief financial officer now owns 68,333 shares in the company, valued at $876,712.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Houte Hans Van sold 3,499 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total value of $44,892.17. Following the transaction, the chief financial officer now directly owns 68,333 shares in the company, valued at $876,712.39. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christine Ring sold 1,900 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $17.01, for a total transaction of $32,319.00. Following the transaction, the insider now owns 19,838 shares in the company, valued at $337,444.38. The disclosure for this sale can be found here. Insiders have sold a total of 10,789 shares of company stock valued at $152,023 over the last 90 days. 9.80% of the stock is owned by corporate insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.